Reaction

Atypical Pneumonia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,942 reports · 116 co-occurring drugs

As of the last recalculation, Atypical Pneumonia appears in 2,942 FAERS reports alongside 116 co-occurring drug terms. The strongest observed disproportionality signal is POSACONAZOLE DELAYED-RELEASE (PRR 14.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Posaconazole Delayed-Release	23	14.9	15.0
Bendamustine Hcl	30	13.8	13.8
Cladribine	15	11.1	11.1
Posaconazole	25	11.0	11.0
Acetylcysteine	14	10.6	10.6
Human Immunoglobulin G	30	10.4	10.4
Diphenhydramine Hydrochloride Capsule, Liquid Filled	30	10.0	10.0
Calcium, Magnesium, Potassium, And Sodium Oxybates	11	9.1	9.1
Thiotepa	12	8.9	8.9
Azacitidine For	22	8.6	8.6
Budesonide, Glycopyrrolate, And Formoterol Fumarate	11	7.5	7.5
Ocrelizumab	63	7.3	7.3
Polatuzumab Vedotin	10	7.3	7.3
Moxifloxacin	14	7.1	7.1
Azacitidine	28	6.7	6.7
Adrenalinum	39	6.7	6.7
Alemtuzumab	18	6.6	6.6
Atovaquone	7	6.2	6.2
Cytarabine	50	6.0	6.0
Canakinumab	9	5.9	5.9
Diphenhydramine	51	5.8	5.8
Selinexor	7	5.7	5.7
Exemestane	17	5.6	5.6
Obinutuzumab	13	5.6	5.6
Ganciclovir	8	5.5	5.5
Azelastine	14	5.5	5.5
Amoxicillin And Clavulanate Potassium	21	5.5	5.5
Dicyclomine Hydrochloride	11	5.5	5.5
Hydroxyzine Hydrochloride	10	5.4	5.4
Hydroxyzine Hydrochloride Oral	10	5.4	5.4
Ganciclovir Sodium	8	5.4	5.4
Oseltamivir	6	5.3	5.3
Epinephrine	48	5.3	5.3
Lidocaine	42	5.2	5.2
Ofatumumab	24	5.1	5.1
Doxyclycline Hyclate	12	5.0	5.0
Benralizumab	14	5.0	5.0
Venetoclax	42	4.9	4.9
Benzonatate	11	4.7	4.7
Thyroid, Porcine	7	4.7	4.7
Valganciclovir Hydrochloride Powder,	8	4.7	4.7
Ropinirole	10	4.6	4.6
Agalsidase Beta	6	4.6	4.6
Buspirone Hydrochloride	7	4.5	4.5
Quinapril Hydrochloride	5	4.5	4.5
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	13	4.5	4.5
Naproxen Sodium, Pseudoephedrine Hydrochloride	13	4.5	4.5
Nebivolol	10	4.5	4.5
Zoledronic Acid	25	4.4	4.4
Carfilzomib	17	4.3	4.3
Voriconazole Injection	13	4.2	4.3
Teduglutide	8	4.2	4.2
Gemcitabine	23	4.2	4.2
Sodium Oxybate	38	4.1	4.1
Melphalan	13	4.1	4.1
Fludarabine Phosphate	22	4.0	4.0
Fluticasone Propionate And Salmeterol	23	3.9	3.9
Everolimus	28	3.9	3.9
Voriconazole	16	3.7	3.7
Baricitinib	5	3.7	3.7
Pemetrexed	11	3.6	3.6
Encorafenib	5	3.6	3.6
Selexipag	13	3.6	3.6
Vedolizumab	43	3.6	3.6
Fluticasone Furoate And Vilanterol Trifenatate	18	3.6	3.6
Bendamustine Hydrochloride	6	3.5	3.6
Gemcitabine Hydrochloride	26	3.5	3.5
Dexamethasone 1.5 Mg	136	3.4	3.4
Granisetron	5	3.4	3.4
Armodafinil	10	3.4	3.4
Bimekizumab	10	3.3	3.3
Ifosfamide	10	3.3	3.3
Atezolizumab	18	3.3	3.3
Ibrutinib	37	3.3	3.3
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	19	3.3	3.3
Levocetirizine Dihydrochloride	11	3.2	3.2
Daratumumab	18	3.2	3.2
Mometasone Furoate And Formoterol Fumarate Dihydrate	7	3.2	3.2
Docetaxel Anhydrous	30	3.2	3.2
Docetaxel	30	3.2	3.2
Ravulizumab	6	3.1	3.1
Belimumab	14	3.1	3.1
Teriflunomide	19	3.0	3.0
Doxorubicin	37	3.0	3.0
Vemurafenib	5	2.9	2.9
Acalabrutinib	5	2.9	2.9
Macitentan	28	2.9	2.9
Risankizumab-Rzaa	32	2.8	2.8
Pomalidomide	39	2.7	2.7
Ivacaftor	3	2.7	2.7
Bortezomib	33	2.6	2.6
Upadacitinib	30	2.6	2.6
Fesoterodine Fumarate	4	2.6	2.6
Pegvaliase-Pqpz	3	2.6	2.6
Iohexol	3	2.6	2.6
Umeclidinium Bromide And Vilanterol Trifenatate	6	2.5	2.5
Nintedanib	11	2.5	2.5
Nivolumab	32	2.4	2.4
Ipilimumab	14	2.3	2.3
Abiraterone Acetate	13	2.2	2.2
Rimegepant Sulfate	4	2.2	2.2
Ambrisentan	38	2.2	2.2
Axicabtagene Ciloleucel	3	2.2	2.2
Eltrombopag Olamine	7	2.2	2.2
Fam-Trastuzumab Deruxtecan-Nxki	3	2.1	2.1
Paricalcitol	4	2.0	2.0
Osimertinib	9	2.0	2.0
Lenalidomide	108	1.8	1.8
Guselkumab	9	1.8	1.8
Abemaciclib	5	1.8	1.8
Pegfilgrastim	24	1.7	1.7
Patiromer	3	1.5	1.5
Dornase Alfa	4	1.4	1.4
Dupilumab	93	1.4	1.4
Galcanezumab-Gnlm	6	1.3	1.3
Voxelotor	4	1.3	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.